Atopic Dermatitis

BOSTON — Children with atopic disease had increased risks for developing eosinophilic esophagitis, according to an abstract presented at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.

Nearly half of patients with head and neck atopic dermatitis who were treated with tralokinumab reported disease clearance after 9 months, according to a presentation at the European Academy of Dermatology and Venereology Congress.

The National Eczema Association has dedicated October to raising awareness of this inflammatory skin condition, with 2024 focused on reducing stigma using social media.

Zabalafin hydrogel clinically improved itch and quality of life among pediatric and adult patients with atopic dermatitis, according to interim results presented at the European Academy of Dermatology and Venerology Congress.

Atopic dermatitis appears to have a significant yet unidirectional causal effect on the risk for keratoconus, according to a study published in Translational Vision Science & Technology.

Researchers found that children diagnosed with food allergy by age 6 months were eight times more likely to develop atopic dermatitis by age 1 year vs. those with no disease.

Orismilast outperformed placebo in the treatment of moderate to severe atopic dermatitis in adults, according to a poster presented at the European Academy of Dermatology and Venereology Congress.

Healio has compiled September’s most-read news in asthma and allergy.

New interim, long-term results showed that nemolizumab improved signs and symptoms of atopic dermatitis including sleep, itch and quality of life, according to a presentation at the European Academy of Dermatology and Venereology Congress.

Dupilumab was safe and effective in treating a group of six children and young adults with inborn errors of immunity and moderate to severe atopic dermatitis, according to a study published in Pediatric Allergy and Immunology.